Bio-Rad Laboratories (BIO) vs Nautilus Biotechnology (NAUT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bio-Rad Laboratories (BIO) has outperformed Nautilus Biotechnology (NAUT) over the past year, gaining 13.3% versus a loss of 5.4%. Over five years, BIO leads with a -52.2% price change compared with -56.4% for NAUT. Bio-Rad Laboratories is the larger company by market cap ($9.65 billion vs $270.0 million), about 35.7 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIO | NAUT |
|---|---|---|
| Share price | $358.90 | $2.12 |
| Market cap | $9.65B | $270.03M |
| 1-day change | -2.34% | -2.30% |
| YTD return | +18.45% | +8.72% |
| 1-year return | +13.32% | -5.36% |
| 5-year return | -52.16% | -56.38% |
| P/E ratio (TTM) | 9.54 | — |
| Forward P/E | 36.23 | — |
| EPS (TTM) | $37.64 | $-0.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.58B | — |
| Revenue growth (YoY) | +0.65% | — |
| Net income (latest FY) | $759.90M | $-59.00M |
| Gross margin | 51.87% | — |
| Operating margin | 1.83% | — |
| Net margin | 29.42% | — |
| 52-week high | $396.23 | $4.31 |
| 52-week low | $236.73 | $0.841 |
| Distance from 52-week high | -9.42% | -50.81% |
| Analyst consensus | hold | none |
| Avg. price target upside | -0.62% | +88.68% |
| Average volume | 257.70K | 6.25M |
| Shares outstanding | 21.83M | 127.37M |
| Employees | 7,450 | 128 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bio-Rad Laboratories is about 35.7 times larger than Nautilus Biotechnology by market value ($9.65B vs $270.03M).
- BIO has outperformed NAUT by 18.7 percentage points over the past year.
About Bio-Rad Laboratories
BIO stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees
About Nautilus Biotechnology
NAUT stock →Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
Industrials · Biotechnology: Laboratory Analytical Instruments · 128 employees
BIO vs NAUT FAQ
Which is bigger, Bio-Rad Laboratories or Nautilus Biotechnology?
Bio-Rad Laboratories (BIO) is larger, with a market capitalization of $9.65B compared with $270.03M for Nautilus Biotechnology (NAUT).
Which stock has performed better over the past year, BIO or NAUT?
BIO returned +13.32% over the past 12 months, compared with -5.36% for NAUT (price return, excluding dividends). Past performance does not predict future results.
Are Bio-Rad Laboratories and Nautilus Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.